EPISODE · Jan 10, 2025 · 3 MIN
#14: Citius Oncology's LYMPHIR™ Launch Strategy
Citius Oncology is preparing to launch LYMPHIR™, a novel treatment for cutaneous T-cell lymphoma (CTCL), and is simultaneously exploring strategic options to maximize its market impact. These options include partnerships and acquisitions to bolster its position within the $400 million CTCL market. The company is focusing on a targeted launch strategy that includes patient support programs and securing international licensing agreements. Their aim is to provide patients with a much-needed therapy while increasing shareholder value. This launch follows years of development and regulatory hurdles. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
#14: Citius Oncology's LYMPHIR™ Launch Strategy
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m